Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer

doi:10.4251/wjgo.v15.i11.1925

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1767)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

WORD

HTML

868

Figures (1-1)

170

Tables (1-6)

161

Sum=1269

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

342

Sum=441

Nov 15, 2023 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1925-1935
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1925

Table 3 Comparison of serum carcinoembryonic antigen, carbohydrate antigen 199, and carbohydrate antigen 125 levels

Indicators	Time	Observation group, n = 46	Control group, n = 46	t	P value
CEA in ng/mL	Before treatment	119.16 ± 18.54	120.06 ± 18.91	0.230	0.818
CEA in ng/mL	After treatment	52.17 ± 7.40¹	71.24 ± 10.22¹	110.250	0.000
CA199 in IU/mL	Before treatment	120.16 ± 20.41	120.55 ± 20.59	0.091	0.928
CA199 in IU/mL	After treatment	51.37 ± 10.22¹	62.47 ± 14.04¹	4.335	0.000
CA125 in U/mL	Before treatment	247.56 ± 25.47	246.91 ± 25.21	0.123	0.902
CA125 in U/mL	After treatment	69.14 ± 10.09¹	88.15 ± 14.53¹	7.288	0.000

¹Denotes a comparison with the pre-treatment values. Data are mean ± SD. CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen.

Citation: Feng R, Cheng DX, Chen XC, Yang L, Wu H. Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1925-1935
URL: https://www.wjgnet.com/1948-5204/full/v15/i11/1925.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i11.1925